$2.23
3.72% yesterday
Nasdaq, May 02, 10:00 pm CET
ISIN
US0070251097
Symbol
ADTX
Sector
Industry

Aditx Therapeutics Inc Stock price

$2.23
-2.77 55.40% 1M
-120.27 98.18% 6M
-45.22 95.30% YTD
-24,697.77 99.99% 1Y
-6,523,997.77 100.00% 3Y
-101,199,997.77 100.00% 5Y
-101,199,997.77 100.00% 10Y
Nasdaq, Closing price Fri, May 02 2025
+0.08 3.72%
ISIN
US0070251097
Symbol
ADTX
Sector
Industry

Key metrics

Market capitalization $252.78m
Enterprise Value $266.66m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2,051.23
P/S ratio (TTM) P/S ratio 1,944.46
P/B ratio (TTM) P/B ratio 0.58
Revenue growth (TTM) Revenue growth -79.23%
Revenue (TTM) Revenue $130.00k
EBIT (operating result TTM) EBIT $-27.86m
Free Cash Flow (TTM) Free Cash Flow $-16.76m
Cash position $830.00k
EPS (TTM) EPS $-161,133.91
Short interest 19.75%
Show more

Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aditx Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aditx Therapeutics Inc:

Buy
100%

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.13 0.13
80% 80%
100%
- Direct Costs 1.24 1.24
5% 5%
954%
-1.11 -1.11
71% 71%
-854%
- Selling and Administrative Expenses 15 15
14% 14%
11,731%
- Research and Development Expense 11 11
54% 54%
8,377%
-27 -27
7% 7%
-20,962%
- Depreciation and Amortization 0.62 0.62
15% 15%
477%
EBIT (Operating Income) EBIT -28 -28
7% 7%
-21,434%
Net Profit -34 -34
6% 6%
-26,500%

In millions USD.

Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aditx Therapeutics Inc Stock News

Neutral
Business Wire
about 14 hours ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt's CIO Dr. Shahrokh Shabahang, and Adimune's Co-CEO Dr. Friedrich Kapp, will join today's Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly...
Neutral
Business Wire
16 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 20...
Neutral
Business Wire
17 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has received Institutional Review Board (IRB) approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic® Endometriosis Test (ME...
More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office United States
CEO Amro Albanna
Employees 26
Founded 2017
Website www.aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today